01/01/2024 Oncology Report
Overview of Studies
A total of four phase 1, three phase 1/2, 16 phase 2, and five phase 3 studies were located.
Of these, six studies were determined to have High Impact Potential. These studies covered various cancer types, including melanoma, blood cancers (myelodysplastic syndromes and chronic myelomonocytic leukemia), nasopharyngeal carcinoma, gastric cancer, cervical cancer, pancreatic cancer, and HPV+ oropharyngeal squamous cell carcinoma. The treatments evaluated in these studies included combinations of chemotherapy, immunotherapy, and targeted therapy. Each study focused on different aspects, such as efficacy, safety, treatment protocols, and survival outcomes, contributing significantly to oncology research and clinical practice.
An additional 20 studies were determined to have Medium Impact potential. These studies covered various cancer types, including follicular lymphoma, soft tissue sarcoma, nasopharyngeal carcinoma, renal cell carcinoma, esophageal squamous cell carcinoma, gastric cancer, non-small cell lung cancer, and ER+/HER2- advanced breast cancer. The treatments investigated include combinations of drugs like rituximab, immunotherapies, nab-paclitaxel, gemcitabine, nimotuzumab, avelumab, axitinib, and others. Each study provides insights into the efficacy, safety, and potential of these treatments in specific cancer types, with an overall medium impact assessment.
Finally, two studies were determined to have Low Impact Potential. The first study evaluates sabatolimab in combination with hypomethylating agents for higher-risk myelodysplastic syndromes (MDS). The second study investigates the combination of entinostat, a histone deacetylase inhibitor, and pembrolizumab, an anti-PD1 antibody, for treating MDS and acute myeloid leukemia (AML) refractory to hypomethylating agents. Both studies report limited efficacy and highlight the need for further research in these areas.
